This issue of memo inHaematology summarizes key findings from studies presented at EHA2024, including results from ongoing and recent clinical trials on the use of monotherapies and combination therapies with Bruton’s tyrosine kinase (BTK) inhibitors and B-cell lymphoma 2 inhibitors (Bcl2i) for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). In addition, it includes real-world insights into the sequencing of therapies in CLL/SLL. The report also features two studies highlighting the potential of BTK degraders for treating CLL/SLL and other B-cell malignancies.